A citation-based method for searching scientific literature

Huju Chi, Chunman Li, Flora Sha Zhao, Li Zhang, Tzi Bun Ng, Guangyi Jin, Ou Sha. Front Pharmacol 2017
Times Cited: 95







List of co-cited articles
1146 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


TLR7/8-agonist-loaded nanoparticles promote the polarization of tumour-associated macrophages to enhance cancer immunotherapy.
Christopher B Rodell, Sean P Arlauckas, Michael F Cuccarese, Christopher S Garris, Ran Li, Maaz S Ahmed, Rainer H Kohler, Mikael J Pittet, Ralph Weissleder. Nat Biomed Eng 2018
383
17

Intratumoral immunotherapy with TLR7/8 agonist MEDI9197 modulates the tumor microenvironment leading to enhanced activity when combined with other immunotherapies.
Stefanie R Mullins, John P Vasilakos, Katharina Deschler, Iwen Grigsby, Pete Gillis, Julius John, Matthew J Elder, John Swales, Elina Timosenko, Zachary Cooper,[...]. J Immunother Cancer 2019
70
17

Structural Analysis Reveals that Toll-like Receptor 7 Is a Dual Receptor for Guanosine and Single-Stranded RNA.
Zhikuan Zhang, Umeharu Ohto, Takuma Shibata, Elena Krayukhina, Masato Taoka, Yoshio Yamauchi, Hiromi Tanji, Toshiaki Isobe, Susumu Uchiyama, Kensuke Miyake,[...]. Immunity 2016
200
10

Oral resiquimod in chronic HCV infection: safety and efficacy in 2 placebo-controlled, double-blind phase IIa studies.
Paul J Pockros, Dominque Guyader, Heather Patton, Myron J Tong, Terry Wright, John G McHutchison, Tze-Chiang Meng. J Hepatol 2007
151
10

Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway.
Hiroaki Hemmi, Tsuneyasu Kaisho, Osamu Takeuchi, Shintaro Sato, Hideki Sanjo, Katsuaki Hoshino, Takao Horiuchi, Hideyuki Tomizawa, Kiyoshi Takeda, Shizuo Akira. Nat Immunol 2002
9

The pharmacokinetics of Toll-like receptor agonists and the impact on the immune system.
Abbi L Engel, Gregory E Holt, Hailing Lu. Expert Rev Clin Pharmacol 2011
113
9

Cancer immunotherapy using checkpoint blockade.
Antoni Ribas, Jedd D Wolchok. Science 2018
9

Toll-like receptor agonists in cancer therapy.
Sylvia Adams. Immunotherapy 2009
183
9

First in human phase I trial of 852A, a novel systemic toll-like receptor 7 agonist, to activate innate immune responses in patients with advanced cancer.
Arkadiusz Z Dudek, Carla Yunis, Lester I Harrison, Sandeep Kumar, Ronald Hawkinson, Sarah Cooley, John P Vasilakos, Kevin S Gorski, Jeffrey S Miller. Clin Cancer Res 2007
114
9

Topical resiquimod can induce disease regression and enhance T-cell effector functions in cutaneous T-cell lymphoma.
Alain H Rook, Joel M Gelfand, Maria Wysocka, Andrea B Troxel, Bernice Benoit, Christian Surber, Rosalie Elenitsas, Marie A Buchanan, Deborah S Leahy, Rei Watanabe,[...]. Blood 2015
117
9

Systemic delivery of a TLR7 agonist in combination with radiation primes durable antitumor immune responses in mouse models of lymphoma.
Simon J Dovedi, Monique H M Melis, Robert W Wilkinson, Amy L Adlard, Ian J Stratford, Jamie Honeychurch, Timothy M Illidge. Blood 2013
107
9


Toll-like receptor signaling pathways.
Takumi Kawasaki, Taro Kawai. Front Immunol 2014
8

TLR agonists: our best frenemy in cancer immunotherapy.
Sabina Kaczanowska, Ann Mary Joseph, Eduardo Davila. J Leukoc Biol 2013
206
8

Improved survival with ipilimumab in patients with metastatic melanoma.
F Stephen Hodi, Steven J O'Day, David F McDermott, Robert W Weber, Jeffrey A Sosman, John B Haanen, Rene Gonzalez, Caroline Robert, Dirk Schadendorf, Jessica C Hassel,[...]. N Engl J Med 2010
8

T cell-targeting nanoparticles focus delivery of immunotherapy to improve antitumor immunity.
Daniela Schmid, Chun Gwon Park, Christina A Hartl, Nikita Subedi, Adam N Cartwright, Regina Bou Puerto, Yiran Zheng, James Maiarana, Gordon J Freeman, Kai W Wucherpfennig,[...]. Nat Commun 2017
206
8

Delivery technologies for cancer immunotherapy.
Rachel S Riley, Carl H June, Robert Langer, Michael J Mitchell. Nat Rev Drug Discov 2019
701
8

Recent clinical trends in Toll-like receptor targeting therapeutics.
Muhammad Ayaz Anwar, Masaud Shah, Jason Kim, Sangdun Choi. Med Res Rev 2019
118
8

Toll-like receptor 8 senses degradation products of single-stranded RNA.
Hiromi Tanji, Umeharu Ohto, Takuma Shibata, Masato Taoka, Yoshio Yamauchi, Toshiaki Isobe, Kensuke Miyake, Toshiyuki Shimizu. Nat Struct Mol Biol 2015
191
8

The use of TLR7 and TLR8 ligands for the enhancement of cancer immunotherapy.
Evelien L J M Smits, Peter Ponsaerts, Zwi N Berneman, Viggo F I Van Tendeloo. Oncologist 2008
147
7

Recent progress in GM-CSF-based cancer immunotherapy.
Wan-Lun Yan, Kuan-Yin Shen, Chun-Yuan Tien, Yu-An Chen, Shih-Jen Liu. Immunotherapy 2017
105
7

STING agonist formulated cancer vaccines can cure established tumors resistant to PD-1 blockade.
Juan Fu, David B Kanne, Meredith Leong, Laura Hix Glickman, Sarah M McWhirter, Edward Lemmens, Ken Mechette, Justin J Leong, Peter Lauer, Weiqun Liu,[...]. Sci Transl Med 2015
399
7


Resiquimod as an immunologic adjuvant for NY-ESO-1 protein vaccination in patients with high-risk melanoma.
Rachel Lubong Sabado, Anna Pavlick, Sacha Gnjatic, Crystal M Cruz, Isabelita Vengco, Farah Hasan, Meredith Spadaccia, Farbod Darvishian, Luis Chiriboga, Rose Marie Holman,[...]. Cancer Immunol Res 2015
60
11

A phase I clinical trial of imiquimod, an oral interferon inducer, administered daily.
P Savage, V Horton, J Moore, M Owens, P Witt, M E Gore. Br J Cancer 1996
84
8

The future of immune checkpoint therapy.
Padmanee Sharma, James P Allison. Science 2015
7

Effective innate and adaptive antimelanoma immunity through localized TLR7/8 activation.
Manisha Singh, Hiep Khong, Zhimin Dai, Xue-Fei Huang, Jennifer A Wargo, Zachary A Cooper, John P Vasilakos, Patrick Hwu, Willem W Overwijk. J Immunol 2014
94
7


Toll-like receptors.
Kiyoshi Takeda, Tsuneyasu Kaisho, Shizuo Akira. Annu Rev Immunol 2003
7

Tumor-Residing Batf3 Dendritic Cells Are Required for Effector T Cell Trafficking and Adoptive T Cell Therapy.
Stefani Spranger, Daisy Dai, Brendan Horton, Thomas F Gajewski. Cancer Cell 2017
645
7

The Toll for Trafficking: Toll-Like Receptor 7 Delivery to the Endosome.
Carlene Petes, Natalya Odoardi, Katrina Gee. Front Immunol 2017
72
9

The use of Toll-like receptor 7/8 agonists as vaccine adjuvants.
John P Vasilakos, Mark A Tomai. Expert Rev Vaccines 2013
152
7

Targeting Toll-like receptors: emerging therapeutics?
Elizabeth J Hennessy, Andrew E Parker, Luke A J O'Neill. Nat Rev Drug Discov 2010
561
7

Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8.
Florian Heil, Hiroaki Hemmi, Hubertus Hochrein, Franziska Ampenberger, Carsten Kirschning, Shizuo Akira, Grayson Lipford, Hermann Wagner, Stefan Bauer. Science 2004
7

Sequence-specific potent induction of IFN-alpha by short interfering RNA in plasmacytoid dendritic cells through TLR7.
Veit Hornung, Margit Guenthner-Biller, Carole Bourquin, Andrea Ablasser, Martin Schlee, Satoshi Uematsu, Anne Noronha, Muthiah Manoharan, Shizuo Akira, Antonin de Fougerolles,[...]. Nat Med 2005
929
7

The Role of TLRs in Anti-cancer Immunity and Tumor Rejection.
Zuzanna Urban-Wojciuk, Mohd M Khan, Benjamin L Oyler, Robin Fåhraeus, Natalia Marek-Trzonkowska, Aleksandra Nita-Lazar, Ted R Hupp, David R Goodlett. Front Immunol 2019
106
7

Systemic administration of a TLR7 agonist attenuates regulatory T cells by dendritic cell modification and overcomes resistance to PD-L1 blockade therapy.
Naoto Nishii, Hidetake Tachinami, Yuta Kondo, Yulong Xia, Yoshihisa Kashima, Tatsukuni Ohno, Shigenori Nagai, Lixin Li, Walter Lau, Hiroyuki Harada,[...]. Oncotarget 2018
21
33


TLR7 and TLR8 as targets in cancer therapy.
M P Schön, M Schön. Oncogene 2008
209
6

Pathogen recognition and innate immunity.
Shizuo Akira, Satoshi Uematsu, Osamu Takeuchi. Cell 2006
6

Cytokines in cancer immunotherapy.
Sylvia Lee, Kim Margolin. Cancers (Basel) 2011
346
6

Delivering safer immunotherapies for cancer.
Lauren Milling, Yuan Zhang, Darrell J Irvine. Adv Drug Deliv Rev 2017
146
6

Understanding the tumor immune microenvironment (TIME) for effective therapy.
Mikhail Binnewies, Edward W Roberts, Kelly Kersten, Vincent Chan, Douglas F Fearon, Miriam Merad, Lisa M Coussens, Dmitry I Gabrilovich, Suzanne Ostrand-Rosenberg, Catherine C Hedrick,[...]. Nat Med 2018
6

PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome.
Hashem O Alsaab, Samaresh Sau, Rami Alzhrani, Katyayani Tatiparti, Ketki Bhise, Sushil K Kashaw, Arun K Iyer. Front Pharmacol 2017
770
6

Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia.
Shannon L Maude, Theodore W Laetsch, Jochen Buechner, Susana Rives, Michael Boyer, Henrique Bittencourt, Peter Bader, Michael R Verneris, Heather E Stefanski, Gary D Myers,[...]. N Engl J Med 2018
6

Therapeutic cancer vaccines: past, present, and future.
Chunqing Guo, Masoud H Manjili, John R Subjeck, Devanand Sarkar, Paul B Fisher, Xiang-Yang Wang. Adv Cancer Res 2013
293
6

Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma.
Sattva S Neelapu, Frederick L Locke, Nancy L Bartlett, Lazaros J Lekakis, David B Miklos, Caron A Jacobson, Ira Braunschweig, Olalekan O Oluwole, Tanya Siddiqi, Yi Lin,[...]. N Engl J Med 2017
6

Trial watch: FDA-approved Toll-like receptor agonists for cancer therapy.
Erika Vacchelli, Lorenzo Galluzzi, Alexander Eggermont, Wolf Hervé Fridman, Jerome Galon, Catherine Sautès-Fridman, Eric Tartour, Laurence Zitvogel, Guido Kroemer. Oncoimmunology 2012
154
6

Vaccine adjuvant uses of poly-IC and derivatives.
Karen A O Martins, Sina Bavari, Andres M Salazar. Expert Rev Vaccines 2015
116
6

Class IIa HDAC inhibition reduces breast tumours and metastases through anti-tumour macrophages.
Jennifer L Guerriero, Alaba Sotayo, Holly E Ponichtera, Jessica A Castrillon, Alexandra L Pourzia, Sara Schad, Shawn F Johnson, Ruben D Carrasco, Suzan Lazo, Roderick T Bronson,[...]. Nature 2017
294
6


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.